These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 36261277)

  • 1. Effect of interrupting methotrexate treatment on COVID-19 booster vaccine response.
    Drug Ther Bull; 2022 Nov; 60(11):163. PubMed ID: 36261277
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).
    Abhishek A; Boyton RJ; McKnight Á; Coates L; Bluett J; Barber VS; Cureton L; Francis A; Appelbe D; Eldridge L; Julier P; Peckham N; Valdes AM; Rombach I; Altmann DM; Nguyen-Van-Tam J; Williams HC; Cook JA
    BMJ Open; 2022 May; 12(5):e062599. PubMed ID: 35504634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment.
    Sparks JA; Tedeschi SK
    Lancet Respir Med; 2022 Sep; 10(9):813-815. PubMed ID: 35772415
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine.
    Granwehr BP
    Ann Intern Med; 2021 Nov; 174(11):JC123. PubMed ID: 34724407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molnupiravir provides little benefit in vaccinated adults with COVID-19.
    Drug Ther Bull; 2023 Jun; 61(6):84. PubMed ID: 37068918
    [No Abstract]   [Full Text] [Related]  

  • 8. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.
    Habermann E; Gieselmann L; Tober-Lau P; Klotsche J; Albach FN; Ten Hagen A; Zernicke J; Ahmadov E; Arumahandi de Silva AN; Frommert LM; Kurth F; Sander LE; Burmester GR; Klein F; Biesen R
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stressing the personal benefits of the covid-19 vaccine might encourage more people to accept it.
    Saul H; Gursul D
    BMJ; 2021 Dec; 375():n2923. PubMed ID: 34893477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
    Li JX; Wu SP; Guo XL; Tang R; Huang BY; Chen XQ; Chen Y; Hou LH; Liu JX; Zhong J; Pan HX; Shi FJ; Xu XY; Li ZP; Zhang XY; Cui LB; Tan WJ; Chen W; Zhu FC;
    Lancet Respir Med; 2022 Aug; 10(8):739-748. PubMed ID: 35605625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients.
    Tunbridge M; Perkins GB; Singer J; Salehi T; Ying T; Grubor-Bauk B; Barry S; Sim B; Hissaria P; Chadban SJ; Coates PT
    Trials; 2022 Sep; 23(1):780. PubMed ID: 36109788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interrupting methotrexate to improve immunity after COVID-19 booster vaccination: is it really worth it?
    Jorda A; Zeitlinger M
    Lancet Respir Med; 2022 Sep; 10(9):e80. PubMed ID: 36057280
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis.
    Stahl D; Tho Pesch C; Brück C; Esser RL; Thiele J; Di Cristanziano V; Kofler DM
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d.
    Schectman JM
    Ann Intern Med; 2023 Feb; 176(2):JC17. PubMed ID: 36745891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Usability, and Acceptability of a Chatbot for Promoting COVID-19 Vaccination in Unvaccinated or Booster-Hesitant Young Adults: Pre-Post Pilot Study.
    Luk TT; Lui JHT; Wang MP
    J Med Internet Res; 2022 Oct; 24(10):e39063. PubMed ID: 36179132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.